Hou (2020)
Risk factors for disease progression in hospitalized patients with COVID-19: a retrospective cohort study
https://doi.org/10.1080/23744235.2020.1759817
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212540/
Laboratory Findings
Lymphocyte count (Abnormal vs. Normal)
COVID-19 (clinical improvement)
Odds ratio: 3.397 (1.195-9.565) Adjusted model

China

Retrospective cohort study

Medical records

101

Based on the clinical types, the patients were divided into a progression group and an improvement group. The definition of the progression group: clinically advanced types; patients admitted to ICU; death during hospitalization. The improvement group: the clinical types remained unchanged or changed to a lighter type, and patients were discharged from the hospital.

The study population included 101 hospitalized patients with laboratory-confirmed COVID-19, and 44 (43.6%) were men. The median age was 50.9±20.1years, and 27 patients were aged >=65 years (26.7%). Among the 101 patients, there were 4 patients with the mild type (4.0%), 75 patients with the common type (74.3%), 13 patients with the severe type (12.9%), and nine patients with the critically ill type (8.9%) at admission. Multivariable logistic regression and ROC curve analysis were performed to explore the risk factors for disease progression.

Total

60 Day


COVID-19 (clinical improvement)

17

17 patients developed disease progression after admission. Clinically advanced types; patients admitted to ICU; death during hospitalization. 6 were transferred to ICU, and five patients died.


Laboratory Findings

Lymphocyte count

Lymphocyte count (× 109/L) >=1.1 vs. <1.1 Lymphocyte count is another predictor of disease progression.

Normal

Abnormal


Odds ratio

3.397 (1.195-9.565)

No

Yes

Yes

Age, CRP, and lymphocyte count


the multivariate analysis is probably misinterpreted, categories are mixed up. Outcome is selected as per curator's decision and not as described in the article.

Poor

Yes